A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with Oligodendroglioma

Robert B. Jenkins, Hilary Blair, Karla V. Ballman, +9

Cancer Research

Validation of EORTC Prognostic Factors for Adults With Low-Grade Glioma: A Report Using Intergroup 86-72-51

T.B. Daniels, Paul D. Brown, Sara J. Felten, +7

International Journal of Radiation Oncology*Biology*Physics

Eortc Prognostic FactorsMedicineLow-grade GliomaCancer ManagementPrognosis +7

Detrimental Effects of Tumor Progression on Cognitive Function of Patients With High-Grade Glioma

Paul D. Brown, Ashley W. Jensen, Sara J. Felten, +5

Journal of Clinical Oncology

Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer

Matthew P. Goetz, Krishna R. Kalari, Vera J. Suman, +32

JNCI Journal of the National Cancer Institute

Relationship between cytokine gene single nucleotide polymorphisms and symptom burden and quality of life in lung cancer survivors

Sarah M. Rausch, Matthew M. Clark, Christi A. Patten, +5

Cancer

The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab

Raymond Y. Huang, Rifaquat Rahman, Karla V. Ballman, +11

Clinical Cancer Research

SNPs in PTGS2 and LTA predict pain and quality of life in long term lung cancer survivors

Sarah M. Rausch, Brian D. Gonzalez, Matthew M. Clark, +6

Lung Cancer

MedicinePathologyCancer GenomicsCancer GeneticsMolecular Diagnostics +4

Evaluation of Lapatinib and Topotecan Combination Therapy: Tissue Culture, Murine Xenograft, and Phase I Clinical Trial Data

Julian R. Molina, Scott H. Kaufmann, Joel M. Reid, +12

Clinical Cancer Research

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors

Joleen M. Hubbard, Charles Erlichman, David O. Toft, +7

Investigational New Drugs

Gemcitabine And/or CisplatinMedicineCancer Management17-Allylamino-17 DemethoxygeldanamycinPathology +5

Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results

Marta Santisteban, Jan C. Buckner, Joel M. Reid, +8

Journal of Neuro-Oncology

Recurrent GliomaOncologyPhase Ii TrialMedicineMetronomic Therapy +7